$39.85
0[0.00%]
At close: Apr 24
$39.85
0[0.00%]
PreMarket: 4:00PM EDT
IDEAYA Biosciences
(NASDAQ:IDYA)Latest News for IDEAYA Biosciences Stock (NASDAQ:IDYA)
IDEAYA Biosciences Stock (NASDAQ: IDYA)
Categories: All
Wednesday, April 24, 2024
Thursday, March 21, 2024
Friday, March 08, 2024
Wednesday, February 21, 2024
Tuesday, February 20, 2024
- Recap: IDEAYA Biosciences Q4 EarningsBenzinga Insights - Feb 20, 2024, 4:45PM
- IDEAYA Biosciences' Cash Balance As Of December 31, 2023 Of $632.6M, Supplemented By Net Proceeds Of $342.3M From January 2024 Atm Offerings, Expected To Fund Operations Into 2028Benzinga Newsdesk - Feb 20, 2024, 6:03AM
- IDEAYA Biosciences Q4 EPS $(0.52) Misses $(0.47) Estimate, Sales $3.92M Miss $8.84M EstimateBenzinga Newsdesk - Feb 20, 2024, 6:02AM
Friday, January 26, 2024
Thursday, January 25, 2024
Friday, January 12, 2024
Wednesday, January 10, 2024
Wednesday, December 06, 2023
Thursday, November 30, 2023
Monday, November 13, 2023
Wednesday, November 08, 2023
Tuesday, November 07, 2023
Wednesday, October 25, 2023
- Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionLisa Levin - Oct 25, 2023, 1:49PM
- Why IDEAYA Biosciences Stock Is Falling During Wednesday's SessionHenry Khederian - Oct 25, 2023, 10:44AM
- IDEAYA shares are trading lower after the company announced it intends to offer and sell up to $125 million of shares of its common stock.Benzinga Newsdesk - Oct 25, 2023, 8:42AM
- Alphabet, Texas Instruments, CoStar Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionLisa Levin - Oct 25, 2023, 5:49AM
Tuesday, October 24, 2023
- IDEAYA shares are trading lower after the company announced it intends to offer and sell up to $125 million of shares of its common stock.Benzinga Newsdesk - Oct 24, 2023, 4:37PM
- IDEAYA Intends To Offer And Sell Up To $125M Of Shares Of Its Common Stock And, In Lieu Of Common Stock, To Offer And Sell To Certain Investors Pre-funded WarrantsBenzinga Newsdesk - Oct 24, 2023, 4:13PM
- RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $36Benzinga Newsdesk - Oct 24, 2023, 12:22PM
Monday, October 23, 2023
Tuesday, October 17, 2023
- IDEAYA Biosciences shares are trading higher after the company announced a proffered paper oral presentation at ESMO 2023 for a Phase 2 clinical data update for darovasertib in combination with crizotinib in metastatic uveal melanoma.Benzinga Newsdesk - Oct 17, 2023, 11:23AM
- Ideaya Biosciences Announces The Publication Of The Abstract For A Proffered Paper Session At The European Society Of Medical Oncology Congress 2023 Relating To Selected Data From Ongoing Phase 2 Trial Of Darovasertib Plus Crizotinib For Metastatic UvealBenzinga Newsdesk - Oct 17, 2023, 6:03AM
Monday, October 16, 2023
Wednesday, October 11, 2023
Wednesday, September 27, 2023
- IDEAYA Targets Program Updates For IDE161 In Q4 Of 2023Benzinga Newsdesk - Sep 27, 2023, 6:03AM
- IDEAYA Gets FDA Fast Track Designation For IDE161 In A Second Indication For The Treatment Of Pretreated, Advanced Or Metastatic HR+, Her2-, BRCA1/2 Mutant Breast CancerBenzinga Newsdesk - Sep 27, 2023, 6:02AM
Tuesday, September 26, 2023
- Ideaya Biosciences Announced CFO Paul A. Stone To Resign Effective As Of November 10, 2023,Charles Gross - Sep 26, 2023, 6:10AM
- Ideaya Receives Fast Track Designation For IDE161 For Pretreated, Platinum-resistant Advanced Or Metastatic Ovarian Cancer Patients Having Tumors With BRCA1/2 MutationsBenzinga Newsdesk - Sep 26, 2023, 6:04AM
Tuesday, September 12, 2023
- 7 Analysts Have This to Say About IDEAYA BiosciencesBenzinga Insights - Sep 12, 2023, 1:00PM
- Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $43Benzinga Newsdesk - Sep 12, 2023, 10:10AM
- Adobe To Rally Over 14%? Here Are 10 Other Analyst Forecasts For TuesdayLisa Levin - Sep 12, 2023, 8:49AM